SCHEMBL17217446

SCHEMBL17217446

Cc1ccccc1CO/N=[C]\c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.40
TAAR1 Q96RJ0 1/20 0.36
CTBP2 P56545 1/20 0.36
ADRA2A P08913 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
CDK4 P11802 1/20 0.35
CCND1 P24385 1/20 0.35
KMT2A Q03164 1/20 0.35
FFAR1 O14842 2/20 0.35
KDM4E B2RXH2 1/20 0.34
S1PR1 P21453 1/20 0.34
S1PR5 Q9H228 1/20 0.34
THRA P10827 1/20 0.33
THRB P10828 1/20 0.33
CYP2A13 Q16696 1/20 0.33
NOTUM Q6P988 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
TACR1 P25103 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17217447 1.00 MAOB (0.40) MAOBTAAR1CTBP2ADRA2AADRA2B
SCHEMBL17218495 0.90 MAOB (0.38) MAOBTAAR1ADRA2AADRA2BADRA2C
SCHEMBL17218492 0.90 MAOB (0.38) MAOBTAAR1ADRA2AADRA2BADRA2C
SCHEMBL17217441 0.87 MAOB (0.36) MAOBTAAR1CTBP2ADRA2AADRA2B
SCHEMBL17216629 0.87 MAOB (0.36) MAOBTAAR1ADRA2AADRA2BADRA2C
SCHEMBL17215907 0.87 TP53 (0.38) MAOBADRA2AADRA2BADRA2CKMT2A
SCHEMBL17215906 0.87 TP53 (0.38) MAOBADRA2AADRA2BADRA2CKMT2A
SCHEMBL17218399 0.87 MAOB (0.42) MAOBKMT2AKDM4EALDH1A1HPGD
SCHEMBL17216631 0.87 MAOB (0.36) MAOBTAAR1ADRA2AADRA2BADRA2C
SCHEMBL17216596 0.87 NPC1 (0.40) MAOBADRA2AADRA2BADRA2CKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2940012-B1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF SUMITOMO CHEMICAL CO (JP) 2019-01-30 EP disclosed
US-9635857-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-05-02 US disclosed
US-9560850-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-02-07 US disclosed
US-20160235065-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-08-18 US disclosed
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-11-26 US disclosed
EP-2940012-A1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF Sumitomo Chemical Company Limited (JP) 2015-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160235065-A1 TETRAZOLINONE COMPOUND AND USE THEREOF MRPS17, TAOK1, TAOK3 MAOB 2207/4885TAAR1 299/4885CTBP2 3658/4885
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF RTN3, CYP51A1, TCOF1 MAOB 3611/4885TAAR1 21/4885CTBP2 2849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.